Annual CFO
-$61.36 M
+$5.14 M+7.74%
December 31, 2023
Summary
- As of February 7, 2025, TCRX annual cash flow from operations is -$61.36 million, with the most recent change of +$5.14 million (+7.74%) on December 31, 2023.
- During the last 3 years, TCRX annual CFO has fallen by -$58.34 million (-1929.71%).
- TCRX annual CFO is now -1929.71% below its all-time high of -$3.02 million, reached on December 31, 2020.
Performance
TCRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$27.92 M
-$1.69 M-6.46%
September 30, 2024
Summary
- As of February 7, 2025, TCRX quarterly cash flow from operations is -$27.92 million, with the most recent change of -$1.69 million (-6.46%) on September 30, 2024.
- Over the past year, TCRX quarterly CFO has dropped by -$35.94 million (-448.24%).
- TCRX quarterly CFO is now -283.13% below its all-time high of $15.24 million, reached on June 30, 2020.
Performance
TCRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$107.18 M
-$35.94 M-50.44%
September 30, 2024
Summary
- As of February 7, 2025, TCRX TTM cash flow from operations is -$107.18 million, with the most recent change of -$35.94 million (-50.44%) on September 30, 2024.
- Over the past year, TCRX TTM CFO has dropped by -$53.57 million (-99.95%).
- TCRX TTM CFO is now -1159.47% below its all-time high of $10.12 million, reached on June 30, 2020.
Performance
TCRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
TCRX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +7.7% | -448.2% | -100.0% |
| 3 y3 years | -1929.7% | -448.2% | -100.0% |
| 5 y5 years | -390.0% | -448.2% | -100.0% |
TCRX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -26.1% | +7.7% | -448.2% | +4.6% | -120.2% | at low |
| 5 y | 5-year | -1929.7% | +7.7% | -283.1% | +4.6% | -1159.5% | at low |
| alltime | all time | -1929.7% | +7.7% | -283.1% | +4.6% | -1159.5% | at low |
TScan Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$27.92 M(+6.5%) | -$107.18 M(+50.4%) |
| Jun 2024 | - | -$26.23 M(-10.4%) | -$71.24 M(+6.3%) |
| Mar 2024 | - | -$29.27 M(+23.1%) | -$67.04 M(+9.3%) |
| Dec 2023 | -$61.36 M(-7.7%) | -$23.77 M(-396.4%) | -$61.36 M(+14.5%) |
| Sep 2023 | - | $8.02 M(-136.4%) | -$53.60 M(-31.8%) |
| Jun 2023 | - | -$22.02 M(-6.6%) | -$78.62 M(+12.4%) |
| Mar 2023 | - | -$23.59 M(+47.3%) | -$69.97 M(+5.2%) |
| Dec 2022 | -$66.50 M | -$16.01 M(-5.8%) | -$66.50 M(+2.5%) |
| Sep 2022 | - | -$17.00 M(+27.2%) | -$64.87 M(+5.5%) |
| Jun 2022 | - | -$13.37 M(-33.6%) | -$61.51 M(+4.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$20.12 M(+39.9%) | -$58.84 M(+20.9%) |
| Dec 2021 | -$48.68 M(+1510.2%) | -$14.38 M(+5.4%) | -$48.68 M(+16.9%) |
| Sep 2021 | - | -$13.64 M(+27.5%) | -$41.65 M(+23.2%) |
| Jun 2021 | - | -$10.70 M(+7.5%) | -$33.80 M(+330.5%) |
| Mar 2021 | - | -$9.96 M(+35.5%) | -$7.85 M(+159.7%) |
| Dec 2020 | -$3.02 M(-75.9%) | - | - |
| Dec 2020 | - | -$7.35 M(+27.0%) | -$3.02 M(-169.9%) |
| Sep 2020 | - | -$5.79 M(-138.0%) | $4.33 M(-57.2%) |
| Jun 2020 | - | $15.24 M(-397.2%) | $10.12 M(-297.2%) |
| Mar 2020 | - | -$5.13 M | -$5.13 M |
| Dec 2019 | -$12.52 M | - | - |
FAQ
- What is TScan Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for TScan Therapeutics?
- What is TScan Therapeutics annual CFO year-on-year change?
- What is TScan Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for TScan Therapeutics?
- What is TScan Therapeutics quarterly CFO year-on-year change?
- What is TScan Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for TScan Therapeutics?
- What is TScan Therapeutics TTM CFO year-on-year change?
What is TScan Therapeutics annual cash flow from operations?
The current annual CFO of TCRX is -$61.36 M
What is the all time high annual CFO for TScan Therapeutics?
TScan Therapeutics all-time high annual cash flow from operations is -$3.02 M
What is TScan Therapeutics annual CFO year-on-year change?
Over the past year, TCRX annual cash flow from operations has changed by +$5.14 M (+7.74%)
What is TScan Therapeutics quarterly cash flow from operations?
The current quarterly CFO of TCRX is -$27.92 M
What is the all time high quarterly CFO for TScan Therapeutics?
TScan Therapeutics all-time high quarterly cash flow from operations is $15.24 M
What is TScan Therapeutics quarterly CFO year-on-year change?
Over the past year, TCRX quarterly cash flow from operations has changed by -$35.94 M (-448.24%)
What is TScan Therapeutics TTM cash flow from operations?
The current TTM CFO of TCRX is -$107.18 M
What is the all time high TTM CFO for TScan Therapeutics?
TScan Therapeutics all-time high TTM cash flow from operations is $10.12 M
What is TScan Therapeutics TTM CFO year-on-year change?
Over the past year, TCRX TTM cash flow from operations has changed by -$53.57 M (-99.95%)